[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350434-105":59,"doc-detail-350434-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","observational-study-of-trastuzumab-biosimilar-in-patients-with-her2-positive-breast-cancer-under-routine-clinical-practice-conditions-in-morocco","Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco","","Background: Trastuzumab has proven benefits in early and metastatic HER2-positive breast cancer, but real-world evidence for biosimilars remains limited. Aim: Confirm tolerance of the trastuzumab biosimilar from Mylan (Hertraz) regarding cardiac safety in HER2-positive patients in routine clinical practice in Morocco. Methods: Prospective, non-interventional, multi-center 12-month follow-up; adults with LVEF ≥50% included; cardiac events, serious/unexpected AEs, drug interactions, chemotherapy, and treatment response collected.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/observational-study-of-trastuzumab-biosimilar-in-patients-with-her2-positive-breast-cancer-under-routine-clinical-practice-conditions-in-morocco/350434/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/observational-study-of-trastuzumab-biosimilar-in-patients-with-her2-positive-breast-cancer-under-routine-clinical-practice-conditions-in-morocco/350434.png","ImageObject",300,407,{"name":92,"@type":93},"Mabel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary objective of the HERLife study?","Question",{"text":112,"@type":113},"To confirm the tolerance of the trastuzumab biosimilar (Mylan Hertraz) with respect to cardiac safety in HER2-positive patients under routine clinical practice in Morocco.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Who were the study participants and what key eligibility criteria were used?",{"text":117,"@type":113},"Adult patients with HER2-positive breast cancer were enrolled, including those aged ≥18 years with left ventricular ejection fraction (LVEF) ≥50%.",{"name":119,"@type":110,"acceptedAnswer":120},"What cardiac and safety outcomes were reported for trastuzumab biosimilar?",{"text":121,"@type":113},"Two patients developed an expected adverse event involving a nonsignificant fall in LVEF, requiring temporary discontinuation for three weeks; no other trastuzumab-related adverse events or drug interactions were reported.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},350434,1790195400,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},7971474920318,"https://ap-avatar.wpscdn.com/avatar/74000ee537e6b0ca360?x-image-process=image/resize,m_fixed,w_180,h_180&k=1788430171632181674","Errihani etal. BMC Cancer (2026) 26:750 BMC Cancer  \n[https://doi.org/10.1186/s12885-026-16005-2](https://doi.org/10.1186/s12885-026-16005-2)  \nRESEARCH Open Access  \nObservational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco  \nHassan Errihani1, Narjiss Berrada2, Meryem El Bachiri3, Hassan Jouhadi4, Omar Kabbaj5, Mouna Bourhafour6, Abdellatif Benider6, Mouna Khouchani7, Ghizlane Belbaraka7, Abdelkader Acharki8, Redouane Samlali4 and Kunvar Harsh Upveja9*  \nAbstract  \nBackground Trastuzumab, a recombinant humanized monoclonal antibody has demonstrated clinical benefits in women with human epidermal growth factor receptor type 2 (HER2)-positive breast cancer in early and metastatic disease settings. However, real-world data on trastuzumab biosimilars are limited. The primary aim of the HERLife study was to confirm the tolerance of trastuzumab biosimilar from Mylan (Hertraz) in terms of cardiac safety in HER2-positive patients diagnosed with early or metastatic breast cancers under routine clinical practice in Morocco. Methods This was a prospective, non-interventional, multi-center, 12-month follow-up study in adult patients with HER2-positive breast cancer treated with trastuzumab biosimilar. Patients aged ≥ 18 years and with left ventricular ejection fraction (LVEF) ≥50% were included. Data on cardiac events, serious or unexpected adverse events (AEs), drug interactions cases, chemotherapy protocols, and response to treatment were collected.  \nResults In total, 99 patients were included (early breast cancer, n = 70; metastatic breast cancer, n = 29) . The median (range) age was 53 (29–76) years. Switching from trastuzumab reference to trastuzumab biosimilar was observed in 32 (32 . 3%) patients in the overall population, including 45 . 0% of metastatic breast cancer and 27 . 0% of early breast cancer patients. Pertuzumab was used in combination with trastuzumab biosimilar in 41.4% and 19. 0% of patients in the metastatic and neoadjuvant settings, respectively. Two patients (2 . 0%) developed an expected AE of a nonsignificant fall in LVEF, requiring temporary discontinuation of trastuzumab biosimilar for three weeks. No other trastuzumab-related AEs or drug interactions were reported. Four patients (26 . 7%) had a pathological complete response in the neoadjuvant group (n = 15) over the 12-month follow-up period.  \nConclusions Trastuzumab biosimilar was found to have acceptable cardiac safety and a comparable profile of efficacy in HER2-positive breast cancer patients in Morocco.  \nKeywords Biosimilar, Breast cancer, HER2-positive, Morocco, Trastuzumab  \n*Correspondence:  \nKunvar Harsh Upveja[kunvarharsh.upveja@biocon.com](kunvarharsh.upveja@biocon.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/","cbCaijdKuvn3M4hp","https://ap.wps.com/l/cbCaijdKuvn3M4hp","pdf",1958199,"English","# Abstract\n# Introduction","[{\"question\":\"What was the primary objective of the HERLife study?\",\"answer\":\"To confirm the tolerance of the trastuzumab biosimilar (Mylan Hertraz) with respect to cardiac safety in HER2-positive patients under routine clinical practice in Morocco.\"},{\"question\":\"Who were the study participants and what key eligibility criteria were used?\",\"answer\":\"Adult patients with HER2-positive breast cancer were enrolled, including those aged ≥18 years with left ventricular ejection fraction (LVEF) ≥50%.\"},{\"question\":\"What cardiac and safety outcomes were reported for trastuzumab biosimilar?\",\"answer\":\"Two patients developed an expected adverse event involving a nonsignificant fall in LVEF, requiring temporary discontinuation for three weeks; no other trastuzumab-related adverse events or drug interactions were reported.\"}]","Observational study of trastuzumab biosimilar in patients with HER2-positive breast cancer under routine clinical practice conditions in Morocco | PDF",1790089004,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e58f5cee067ea468ccc700483a195a66.webp",983,1310,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a3150e33fbf4bb892cb8af24ac9431c2.webp",982,1309,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9021206ad9702eb5d3bfd63113271b41.webp",981,1308,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3866389130e30ef764cd6befd62bcebd.webp",980,1306]